Carcinoma — Research · CancerIndex

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

pubmedComputed14 windows · counts computed by CancerIndex from PubMed E-utilities; the exact query is stored with each count.

Window	Period	Records (count)	Exact query	Computed	Source
All time	… → 2026-09-28	803,466	`("Carcinoma"[mh] OR "Epithelial Neoplasm, Malignant"[mh] OR "Epithelioma"[mh] OR "Epitheliomas"[mh])`	2026-09-28	pubmed
Last 5 years	2021-01-01 → 2026-12-31	142,030	`("Carcinoma"[mh] OR "Epithelial Neoplasm, Malignant"[mh] OR "Epithelioma"[mh] OR "Epitheliomas"[mh]) AND (2021/01/01:2026/12/31[dp])`	2026-09-28	pubmed
Preceding 5-year window	2020-09-28 → 2025-09-27	128,821	`("Carcinoma"[mh] OR "Epithelial Neoplasm, Malignant"[mh] OR "Epithelioma"[mh] OR "Epitheliomas"[mh]) AND (2020/09/28:2025/09/27[dp])`	2026-09-28	pubmed
Last 12 months	2025-09-28 → 2026-09-28	23,487	`("Carcinoma"[mh] OR "Epithelial Neoplasm, Malignant"[mh] OR "Epithelioma"[mh] OR "Epitheliomas"[mh]) AND (2025/09/28:2026/09/28[dp])`	2026-09-28	pubmed
y2016	2016-01-01 → 2016-12-31	27,273	`("Carcinoma"[mh] OR "Epithelial Neoplasm, Malignant"[mh] OR "Epithelioma"[mh] OR "Epitheliomas"[mh]) AND (2016/01/01:2016/12/31[dp])`	2026-09-28	pubmed
y2017	2017-01-01 → 2017-12-31	26,425	`("Carcinoma"[mh] OR "Epithelial Neoplasm, Malignant"[mh] OR "Epithelioma"[mh] OR "Epitheliomas"[mh]) AND (2017/01/01:2017/12/31[dp])`	2026-09-28	pubmed
y2018	2018-01-01 → 2018-12-31	26,662	`("Carcinoma"[mh] OR "Epithelial Neoplasm, Malignant"[mh] OR "Epithelioma"[mh] OR "Epitheliomas"[mh]) AND (2018/01/01:2018/12/31[dp])`	2026-09-28	pubmed
y2019	2019-01-01 → 2019-12-31	28,543	`("Carcinoma"[mh] OR "Epithelial Neoplasm, Malignant"[mh] OR "Epithelioma"[mh] OR "Epitheliomas"[mh]) AND (2019/01/01:2019/12/31[dp])`	2026-09-28	pubmed
y2020	2020-01-01 → 2020-12-31	30,434	`("Carcinoma"[mh] OR "Epithelial Neoplasm, Malignant"[mh] OR "Epithelioma"[mh] OR "Epitheliomas"[mh]) AND (2020/01/01:2020/12/31[dp])`	2026-09-28	pubmed
y2021	2021-01-01 → 2021-12-31	30,227	`("Carcinoma"[mh] OR "Epithelial Neoplasm, Malignant"[mh] OR "Epithelioma"[mh] OR "Epitheliomas"[mh]) AND (2021/01/01:2021/12/31[dp])`	2026-09-28	pubmed
y2022	2022-01-01 → 2022-12-31	30,258	`("Carcinoma"[mh] OR "Epithelial Neoplasm, Malignant"[mh] OR "Epithelioma"[mh] OR "Epitheliomas"[mh]) AND (2022/01/01:2022/12/31[dp])`	2026-09-28	pubmed
y2023	2023-01-01 → 2023-12-31	29,386	`("Carcinoma"[mh] OR "Epithelial Neoplasm, Malignant"[mh] OR "Epithelioma"[mh] OR "Epitheliomas"[mh]) AND (2023/01/01:2023/12/31[dp])`	2026-09-28	pubmed
y2024	2024-01-01 → 2024-12-31	27,686	`("Carcinoma"[mh] OR "Epithelial Neoplasm, Malignant"[mh] OR "Epithelioma"[mh] OR "Epitheliomas"[mh]) AND (2024/01/01:2024/12/31[dp])`	2026-09-28	pubmed
y2025	2025-01-01 → 2025-12-31	26,061	`("Carcinoma"[mh] OR "Epithelial Neoplasm, Malignant"[mh] OR "Epithelioma"[mh] OR "Epitheliomas"[mh]) AND (2025/01/01:2025/12/31[dp])`	2026-09-28	pubmed

Data updated 4 days agoSource updated unknownsource: pubmed E-utilities

Literature

Linked publications (909)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedPublishedShowing 351–375 of 909 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma.
· Br J Cancer · 2019 · PMID 30420614 · validated civic_curation pubmed
Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study.
· Lancet Gastroenterol Hepatol · 2019 · PMID 31300360 · validated civic_curation pubmed
Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer.
· Clin Cancer Res · 2016 · PMID 26920887 · validated civic_curation pubmed
Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer.